HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AKESO

112.100

-3.500-3.03%

Volume:7.89M

Turnover:880.53M

Market Cap:103.24B

PE:-185.42

High:113.200

Open:112.000

Low:109.700

Close:115.600

52wk High:179.000

52wk Low:60.600

Shares:921.00M

HK Float Shares:921.00M

Volume Ratio:1.07

T/O Rate:0.86%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.605

ROE:-14.61%

ROA:-4.41%

PB:14.10

PE(LYR):-185.42

PS:36.14

Loading ...

Overview Company News Filings

Earning Preview: AKESO this quarter’s revenue is expected to increase by 0%, and institutional views are Neutral

Akeso (9926.HK) Schedules 26 Mar 2026 Board Meeting to Approve FY2025 Results

Bulletin Express

Akeso board to review and approve full-year results

AKESO Shares Climb Over 4% Again Following Clinical Trial Approval for First Trispecific Antibody

Akeso wins NMPA IND clearance for AK150 solid tumor trial

AKESO Shares Surge Nearly 8% in Morning Session as First-in-Class Trispecific Antibody AK150 Enters Clinical Trials

Assessing Akeso (SEHK:9926) Valuation After Cervical Cancer Data And New INOVIO Trial Collaboration

Simply Wall St.

AKESO Shares Surge Over 6% in Morning Session on Novel Brain Cancer Treatment Collaboration

Akeso Reports 100% 24-Month Overall Survival in Complete Responders With Cadonilimab in Phase II Cervical Cancer Study

Cadonilimab Achieves 100% 24-Month Os in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase Ii Results

THOMSON REUTERS

Akeso, INOVIO team up to test cadonilimab plus INO-5412 in GBM trial

BRIEF-Inovio And Akeso Announce Clinical Collaboration To Advance Novel Combination Therapy For Glioblastoma (Gbm)

Inovio and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)

THOMSON REUTERS

Inovio - Dosing in Combination Therapy Trial Expected to Begin in H2 2026

THOMSON REUTERS

AKESO (09926) Announces Monthly Return with No Changes to Share Capital or Issued Shares

Bulletin Express

AKESO Shares Climb Nearly 5% in Morning Session Following NDA Acceptance for Mandoqi Monoclonal Antibody

Assessing Akeso (SEHK:9926) Valuation After AK139 Trial Approval And Ivonescimab Breakthrough Designation

Simply Wall St.

Akeso Receives Chinese Approval to Begin Phase II Trials of IL-4Rα/ST2 Bispecific Antibody Across Seven Indications

Akeso Reports Promising Phase III Results for Ivonescimab in Advanced Biliary Tract Cancer

Akeso startet Phase-III-Studie mit Ivonescimab zur Erstlinienbehandlung von fortgeschrittenem Gallengangskrebs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/09926/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09926","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09926\",,,,,undefined,":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"AKESO","latestPrice":112.1,"timestamp":1774253289009,"preClose":115.6,"halted":0,"volume":7889829,"delay":0,"changeRate":-0.030276816608996542,"floatShares":921000000,"shares":921000000,"eps":-0.604581,"marketStatus":"Not Yet Opened","change":-3.5,"latestTime":"03-23 16:08:09","open":112,"high":113.2,"low":109.7,"amount":880533302,"amplitude":0.030277,"askPrice":112.3,"askSize":1000,"bidPrice":112,"bidSize":21000,"shortable":3,"etf":0,"ttmEps":-1.007,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774315800000},"marketStatusCode":0,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":115.6,"openAndCloseTimeList":[[1774229400000,1774238400000],[1774242000000,1774252800000]],"volumeRatio":1.0705718336893182,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.7425,"impliedVolPercentile":0.9767},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09926\",,,,,undefined,":{"symbol":"09926","floatShares":921000000,"roa":"-4.41%","roe":"-14.61%","lyrEps":-0.604581,"volumeRatio":1.0705718336893182,"shares":921000000,"dividePrice":0,"high":113.2,"amplitude":0.030277,"preClose":115.6,"low":109.7,"week52Low":60.6,"pbRate":"14.10","psRate":"36.14","week52High":179,"institutionHeld":0,"latestPrice":112.1,"committee":0.909091,"eps":-0.604581,"divideRate":0,"volume":7889829,"delay":0,"ttmEps":-1.007,"open":112,"prevYearClose":113,"prevWeekClose":115.6,"prevMonthClose":106.9,"prevQuarterClose":113,"fiveDayClose":116.6,"twentyDayClose":109.6,"sixtyDayClose":117.2,"earningDate":1774454400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09926\",params:#limit:5,,,undefined,":[{"date":"2026-03-26","symbol":"09926","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null},{"date":"2025-08-26","symbol":"09926","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null},{"date":"2025-03-30","symbol":"09926","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1743298200000,"name":null,"time":"Post Market","dateTimestamp":1743264000000,"actualEps":null},{"date":"2024-08-28","symbol":"09926","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724808600000,"name":null,"time":"","dateTimestamp":1724774400000,"actualEps":null},{"date":"2024-03-18","symbol":"09926","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1710725400000,"name":null,"time":"","dateTimestamp":1710691200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09926\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09926\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.375,"buy":0.5,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":24,"updateTime":1770825600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09926\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09926","date":"2026-03-20","current":-111.320755,"percent":0.160524,"low":-283.614883,"twenty":-84.977693,"median":-25.773598,"eighty":13.494628,"high":20.221708,"avg":-44.105516,"sd":58.386089,"marketCap":106484151145},"quantilePoints":[{"date":"2021-03-26","current":-37.072786,"twenty":-62.202297,"median":-42.138278,"eighty":-21.221991,"marketCap":39504714459},{"date":"2021-04-01","current":-41.283195,"twenty":-62.015041,"median":-41.751169,"eighty":-21.266862,"marketCap":43875970351},{"date":"2021-04-09","current":-31.196593,"twenty":-61.70772,"median":-41.695813,"eighty":-21.319481,"marketCap":43590000339},{"date":"2021-04-16","current":-30.642009,"twenty":-61.527169,"median":-40.849406,"eighty":-21.393706,"marketCap":42977207457},{"date":"2021-04-23","current":-31.96013,"twenty":-61.441675,"median":-40.344151,"eighty":-21.433299,"marketCap":44938144680},{"date":"2021-04-30","current":-30.816187,"twenty":-61.312504,"median":-39.558199,"eighty":-21.441654,"marketCap":43508294622},{"date":"2021-05-07","current":-28.864106,"twenty":-61.27851,"median":-38.69692,"eighty":-21.489217,"marketCap":41016270235},{"date":"2021-05-14","current":-29.343194,"twenty":-61.208677,"median":-38.024901,"eighty":-21.636828,"marketCap":41669915976},{"date":"2021-05-21","current":-32.815059,"twenty":-61.158545,"median":-37.656345,"eighty":-21.839766,"marketCap":46613111890},{"date":"2021-05-28","current":-34.118192,"twenty":-61.102433,"median":-37.609185,"eighty":-22.049324,"marketCap":48941724842},{"date":"2021-06-04","current":-35.625611,"twenty":-60.979677,"median":-37.553441,"eighty":-22.116923,"marketCap":50861809206},{"date":"2021-06-10","current":-37.08623,"twenty":-60.769842,"median":-37.072786,"eighty":-22.258985,"marketCap":52986157863},{"date":"2021-06-18","current":-35.659842,"twenty":-60.584234,"median":-36.485136,"eighty":-22.270088,"marketCap":50494133476},{"date":"2021-06-25","current":-36.773665,"twenty":-60.537647,"median":-36.47778,"eighty":-22.279086,"marketCap":51923983534},{"date":"2021-06-30","current":-36.160141,"twenty":-60.48212,"median":-36.485136,"eighty":-22.301737,"marketCap":51188632076},{"date":"2021-07-09","current":-33.001535,"twenty":-60.380024,"median":-36.358401,"eighty":-22.333501,"marketCap":46572259032},{"date":"2021-07-16","current":-33.61015,"twenty":-60.247205,"median":-36.160141,"eighty":-22.684742,"marketCap":47430169066},{"date":"2021-07-23","current":-30.660269,"twenty":-60.081955,"median":-36.081197,"eighty":-23.212212,"marketCap":43263177469},{"date":"2021-07-30","current":-29.749657,"twenty":-60.025123,"median":-35.993074,"eighty":-23.780519,"marketCap":42119297422},{"date":"2021-08-06","current":-26.92917,"twenty":-59.948494,"median":-35.665203,"eighty":-24.743522,"marketCap":38034011542},{"date":"2021-08-13","current":-25.592675,"twenty":-59.918873,"median":-35.597545,"eighty":-24.965673,"marketCap":36195632896},{"date":"2021-08-20","current":-20.885732,"twenty":-59.826938,"median":-35.459665,"eighty":-24.434422,"marketCap":29454911194},{"date":"2021-08-27","current":-21.082492,"twenty":-59.613719,"median":-35.394103,"eighty":-23.176546,"marketCap":29863439782},{"date":"2021-09-03","current":-31.115126,"twenty":-59.45425,"median":-35.211108,"eighty":-23.023412,"marketCap":34806635697},{"date":"2021-09-10","current":-32.055246,"twenty":-59.359698,"median":-34.971061,"eighty":-23.122707,"marketCap":35950515744},{"date":"2021-09-17","current":-31.163903,"twenty":-59.210176,"median":-34.572405,"eighty":-23.198629,"marketCap":34847488556},{"date":"2021-09-24","current":-31.295563,"twenty":-59.102123,"median":-34.437371,"eighty":-23.212212,"marketCap":35010899991},{"date":"2021-09-30","current":-31.154784,"twenty":-59.047908,"median":-34.407249,"eighty":-23.447883,"marketCap":34970047132},{"date":"2021-10-08","current":-29.845898,"twenty":-58.976264,"median":-34.085183,"eighty":-24.385279,"marketCap":33499344216},{"date":"2021-10-15","current":-32.807984,"twenty":-58.969537,"median":-33.89682,"eighty":-24.581853,"marketCap":36849278637},{"date":"2021-10-22","current":-33.585285,"twenty":-58.897857,"median":-33.786096,"eighty":-24.856047,"marketCap":37993158684},{"date":"2021-10-29","current":-31.568779,"twenty":-58.531823,"median":-33.627637,"eighty":-25.019036,"marketCap":35623692873},{"date":"2021-11-05","current":-28.336247,"twenty":-58.387259,"median":-33.581277,"eighty":-25.13981,"marketCap":32028641299},{"date":"2021-11-12","current":-31.135474,"twenty":-58.165915,"median":-33.566565,"eighty":-25.305935,"marketCap":35337722862},{"date":"2021-11-19","current":-36.658551,"twenty":-57.747713,"median":-33.576384,"eighty":-25.505551,"marketCap":41547357399},{"date":"2021-11-26","current":-34.737009,"twenty":-57.465203,"median":-33.61015,"eighty":-25.671516,"marketCap":39382155883},{"date":"2021-12-03","current":-31.939354,"twenty":-57.376977,"median":-33.627637,"eighty":-26.141756,"marketCap":36277338614},{"date":"2021-12-10","current":-30.771813,"twenty":-57.264113,"median":-33.577269,"eighty":-26.43668,"marketCap":35010899991},{"date":"2021-12-17","current":-26.05017,"twenty":-56.996271,"median":-33.456271,"eighty":-26.43668,"marketCap":29618322630},{"date":"2021-12-24","current":-24.338156,"twenty":-56.834726,"median":-33.106388,"eighty":-25.505551,"marketCap":27698238266},{"date":"2021-12-31","current":-24.356969,"twenty":-56.799582,"median":-33.044261,"eighty":-25.17902,"marketCap":27779943984},{"date":"2022-01-07","current":-20.242995,"twenty":-23.086945,"median":-21.779811,"eighty":-19.899701,"marketCap":23000159504},{"date":"2022-01-14","current":-20.701287,"twenty":-22.600464,"median":-21.033383,"eighty":-20.391327,"marketCap":23572099527},{"date":"2022-01-21","current":-18.577865,"twenty":-21.986595,"median":-20.680988,"eighty":-19.350843,"marketCap":21202633717},{"date":"2022-01-28","current":-14.534275,"twenty":-21.562934,"median":-20.260299,"eighty":-18.52558,"marketCap":16545407814},{"date":"2022-02-04","current":-14.146452,"twenty":-21.41835,"median":-20.123216,"eighty":-17.613539,"marketCap":16096026367},{"date":"2022-02-11","current":-13.816944,"twenty":-21.209422,"median":-19.299968,"eighty":-14.985471,"marketCap":15752862353},{"date":"2022-02-18","current":-13.849256,"twenty":-20.857344,"median":-18.911796,"eighty":-14.543623,"marketCap":15867250357},{"date":"2022-02-25","current":-14.199347,"twenty":-20.701287,"median":-17.613539,"eighty":-14.146452,"marketCap":16308461232},{"date":"2022-03-04","current":-14.080132,"twenty":-20.680988,"median":-15.318994,"eighty":-14.146452,"marketCap":16177732084},{"date":"2022-03-11","current":-11.936356,"twenty":-20.490215,"median":-14.985471,"eighty":-13.996814,"marketCap":13693878269},{"date":"2022-03-18","current":-11.726724,"twenty":-20.277602,"median":-14.700549,"eighty":-13.379502,"marketCap":13399737686},{"date":"2022-03-25","current":-12.670051,"twenty":-20.242995,"median":-14.554967,"eighty":-13.072377,"marketCap":14478253158},{"date":"2022-04-01","current":-9.59311,"twenty":-20.003436,"median":-14.538949,"eighty":-12.331764,"marketCap":12697068515},{"date":"2022-04-08","current":-10.156641,"twenty":-19.508494,"median":-14.196743,"eighty":-11.833638,"marketCap":13448761116},{"date":"2022-04-14","current":-9.530673,"twenty":-19.333884,"median":-14.131899,"eighty":-11.51878,"marketCap":12599021653},{"date":"2022-04-22","current":-8.780037,"twenty":-19.299831,"median":-14.060726,"eighty":-10.573986,"marketCap":11389777033},{"date":"2022-04-29","current":-9.576611,"twenty":-19.278065,"median":-13.849256,"eighty":-10.115287,"marketCap":12223175352},{"date":"2022-05-06","current":-7.86231,"twenty":-19.112154,"median":-13.498553,"eighty":-9.579911,"marketCap":9951756403},{"date":"2022-05-13","current":-8.110711,"twenty":-18.577865,"median":-13.379502,"eighty":-9.437455,"marketCap":10082485551},{"date":"2022-05-20","current":-9.061494,"twenty":-18.447152,"median":-13.096379,"eighty":-8.947629,"marketCap":11422459320},{"date":"2022-05-27","current":-8.809867,"twenty":-17.613539,"median":-12.670051,"eighty":-8.780037,"marketCap":11095636450},{"date":"2022-06-02","current":-11.227787,"twenty":-16.802517,"median":-12.331764,"eighty":-8.803901,"marketCap":14216794862},{"date":"2022-06-10","current":-12.109337,"twenty":-15.675042,"median":-12.221978,"eighty":-8.825148,"marketCap":15229945760},{"date":"2022-06-17","current":-11.667379,"twenty":-15.244074,"median":-11.936356,"eighty":-8.923897,"marketCap":14658005737},{"date":"2022-06-24","current":-16.485913,"twenty":-15.494316,"median":-12.221978,"eighty":-9.038721,"marketCap":20794105129},{"date":"2022-06-30","current":-14.957001,"twenty":-15.895364,"median":-12.380422,"eighty":-9.079607,"marketCap":18833167906},{"date":"2022-07-08","current":-15.913959,"twenty":-16.531452,"median":-12.638751,"eighty":-9.104893,"marketCap":20058753670},{"date":"2022-07-15","current":-15.322331,"twenty":-16.45611,"median":-12.887919,"eighty":-9.149933,"marketCap":19134050754},{"date":"2022-07-22","current":-14.807486,"twenty":-16.221667,"median":-13.200862,"eighty":-9.216155,"marketCap":18503257872},{"date":"2022-07-29","current":-14.117198,"twenty":-15.979822,"median":-13.449665,"eighty":-9.360153,"marketCap":17662200696},{"date":"2022-08-05","current":-15.298986,"twenty":-15.838747,"median":-13.498553,"eighty":-9.442,"marketCap":19091997895},{"date":"2022-08-12","current":-15.143556,"twenty":-15.77936,"median":-13.923035,"eighty":-9.496416,"marketCap":18923786460},{"date":"2022-08-19","current":-14.616817,"twenty":-15.77936,"median":-14.080132,"eighty":-9.558236,"marketCap":18082729284},{"date":"2022-08-26","current":-14.756101,"twenty":-15.738632,"median":-14.060726,"eighty":-9.58651,"marketCap":21573116564},{"date":"2022-09-02","current":-14.751536,"twenty":-15.714766,"median":-14.080132,"eighty":-9.724865,"marketCap":21489010846},{"date":"2022-09-09","current":-14.98178,"twenty":-15.703366,"median":-14.105484,"eighty":-9.977712,"marketCap":21741327999},{"date":"2022-09-16","current":-13.542084,"twenty":-15.658514,"median":-14.086951,"eighty":-10.115287,"marketCap":19470473624},{"date":"2022-09-23","current":-12.107338,"twenty":-15.550768,"median":-14.041319,"eighty":-10.199224,"marketCap":17073460672},{"date":"2022-09-30","current":-12.91765,"twenty":-15.461818,"median":-13.978573,"eighty":-10.287783,"marketCap":18250940719},{"date":"2022-10-07","current":-16.281937,"twenty":-15.588998,"median":-14.018764,"eighty":-10.343921,"marketCap":23002913763},{"date":"2022-10-14","current":-15.674276,"twenty":-15.588998,"median":-14.040715,"eighty":-10.440625,"marketCap":21909539434},{"date":"2022-10-21","current":-18.781307,"twenty":-15.710601,"median":-14.070137,"eighty":-10.570074,"marketCap":26072772456},{"date":"2022-10-28","current":-18.085263,"twenty":-15.888888,"median":-14.117198,"eighty":-10.76408,"marketCap":25063503844},{"date":"2022-11-04","current":-18.001131,"twenty":-16.380537,"median":-14.170295,"eighty":-10.773453,"marketCap":25189662421},{"date":"2022-11-11","current":-17.246398,"twenty":-16.644748,"median":-14.199347,"eighty":-10.843556,"marketCap":24348605245},{"date":"2022-11-18","current":-21.310798,"twenty":-17.050284,"median":-14.308051,"eighty":-11.043704,"marketCap":29983688324},{"date":"2022-11-25","current":-18.980602,"twenty":-17.498612,"median":-14.382807,"eighty":-11.22006,"marketCap":26493301044},{"date":"2022-12-02","current":-19.013979,"twenty":-17.995008,"median":-14.534799,"eighty":-11.242055,"marketCap":26997935349},{"date":"2022-12-09","current":-24.062263,"twenty":-18.437795,"median":-14.543856,"eighty":-11.359054,"marketCap":34483344216},{"date":"2022-12-16","current":-24.530301,"twenty":-18.889555,"median":-14.574904,"eighty":-11.602588,"marketCap":35072084239},{"date":"2022-12-23","current":-25.228352,"twenty":-19.041941,"median":-14.612379,"eighty":-11.627361,"marketCap":36081352850},{"date":"2022-12-30","current":-24.983629,"twenty":-19.09779,"median":-14.616563,"eighty":-11.655751,"marketCap":36165458568},{"date":"2023-01-06","current":-26.109825,"twenty":-19.246994,"median":-14.727609,"eighty":-11.666513,"marketCap":38183995790},{"date":"2023-01-13","current":-27.482086,"twenty":-19.35432,"median":-14.788719,"eighty":-11.675194,"marketCap":40959484471},{"date":"2023-01-20","current":-27.207673,"twenty":-19.72973,"median":-14.927803,"eighty":-11.681264,"marketCap":40202533012},{"date":"2023-01-27","current":-29.02317,"twenty":-19.973183,"median":-14.953302,"eighty":-11.681837,"marketCap":42893915976},{"date":"2023-02-03","current":-27.684735,"twenty":-20.135985,"median":-14.979187,"eighty":-11.694899,"marketCap":41127695906},{"date":"2023-02-10","current":-25.345976,"twenty":-20.490215,"median":-14.987339,"eighty":-11.726724,"marketCap":37427044332},{"date":"2023-02-17","current":-24.322978,"twenty":-20.857344,"median":-15.034554,"eighty":-11.784491,"marketCap":35576718544},{"date":"2023-02-24","current":-24.100109,"twenty":-21.41835,"median":-15.060613,"eighty":-11.860367,"marketCap":34819767086},{"date":"2023-03-03","current":-25.36278,"twenty":-22.807081,"median":-15.131721,"eighty":-11.936356,"marketCap":36880357167},{"date":"2023-03-10","current":-22.900092,"twenty":-23.768741,"median":-23.203261,"eighty":-23.03994,"marketCap":33053547016},{"date":"2023-03-17","current":-29.09369,"twenty":-36.802165,"median":-25.36278,"eighty":-15.020812,"marketCap":38688630096},{"date":"2023-03-24","current":-25.324343,"twenty":-36.777216,"median":-25.389232,"eighty":-15.036479,"marketCap":34062815628},{"date":"2023-03-31","current":-25.456261,"twenty":-36.704597,"median":-25.488573,"eighty":-15.049117,"marketCap":33978709910},{"date":"2023-04-06","current":-27.774061,"twenty":-36.623868,"median":-25.540624,"eighty":-15.058257,"marketCap":37048568602},{"date":"2023-04-14","current":-29.730818,"twenty":-36.485136,"median":-25.637411,"eighty":-15.064541,"marketCap":39697898707},{"date":"2023-04-21","current":-26.784111,"twenty":-36.470425,"median":-25.724076,"eighty":-15.129637,"marketCap":35744929980},{"date":"2023-04-28","current":-27.207269,"twenty":-36.436465,"median":-26.010547,"eighty":-15.131721,"marketCap":36039299991},{"date":"2023-05-05","current":-28.335447,"twenty":-36.311562,"median":-26.064869,"eighty":-15.141189,"marketCap":37595255767},{"date":"2023-05-12","current":-27.159579,"twenty":-36.18971,"median":-26.086367,"eighty":-15.143863,"marketCap":35786982838},{"date":"2023-05-19","current":-24.342298,"twenty":-36.161524,"median":-26.085247,"eighty":-15.156,"marketCap":31623749817},{"date":"2023-05-25","current":-24.063272,"twenty":-36.158475,"median":-26.064869,"eighty":-15.180082,"marketCap":31203221229},{"date":"2023-06-02","current":-23.645458,"twenty":-36.149195,"median":-25.984476,"eighty":-15.257042,"marketCap":30488322630},{"date":"2023-06-09","current":-23.222359,"twenty":-36.112659,"median":-25.723039,"eighty":-15.312993,"marketCap":29899582606},{"date":"2023-06-16","current":-24.58122,"twenty":-36.07905,"median":-25.633881,"eighty":-15.343575,"marketCap":31497591241},{"date":"2023-06-23","current":-21.944137,"twenty":-36.043198,"median":-25.488573,"eighty":-15.365065,"marketCap":27965151102},{"date":"2023-06-30","current":-23.543047,"twenty":-35.998611,"median":-25.389232,"eighty":-15.403178,"marketCap":29731371171},{"date":"2023-07-07","current":-23.989446,"twenty":-35.969849,"median":-25.36278,"eighty":-15.455833,"marketCap":30236005477},{"date":"2023-07-14","current":-24.41425,"twenty":-35.912278,"median":-25.312393,"eighty":-15.498928,"marketCap":31203221229},{"date":"2023-07-21","current":-24.59436,"twenty":-35.843663,"median":-25.202538,"eighty":-15.562817,"marketCap":31287326947},{"date":"2023-07-28","current":-28.426335,"twenty":-35.766034,"median":-25.264398,"eighty":-15.623426,"marketCap":36123405709},{"date":"2023-08-04","current":-24.11733,"twenty":-35.704573,"median":-25.300444,"eighty":-15.66297,"marketCap":30698586924},{"date":"2023-08-11","current":-22.294,"twenty":-35.666275,"median":-25.201022,"eighty":-15.683018,"marketCap":28217468254},{"date":"2023-08-18","current":-21.752014,"twenty":-35.64615,"median":-25.173816,"eighty":-15.703366,"marketCap":27334358220},{"date":"2023-08-25","current":-22.10921,"twenty":-35.616771,"median":-25.07893,"eighty":-15.714766,"marketCap":27796939666},{"date":"2023-09-01","current":13.494719,"twenty":-35.601124,"median":-25.008455,"eighty":-15.66297,"marketCap":28974419713},{"date":"2023-09-08","current":13.695117,"twenty":-35.550756,"median":-24.944029,"eighty":-15.455833,"marketCap":29058525430},{"date":"2023-09-15","current":14.848421,"twenty":-35.47221,"median":-24.903626,"eighty":-15.308324,"marketCap":31749908394},{"date":"2023-09-22","current":14.814862,"twenty":-35.438003,"median":-24.827647,"eighty":-15.14371,"marketCap":31539644100},{"date":"2023-09-29","current":14.197918,"twenty":-35.396385,"median":-24.772153,"eighty":-15.059828,"marketCap":30278058336},{"date":"2023-10-06","current":13.889059,"twenty":-35.370319,"median":-24.700469,"eighty":-15.007069,"marketCap":29605212595},{"date":"2023-10-13","current":15.431226,"twenty":-35.30592,"median":-24.632761,"eighty":-14.979706,"marketCap":32843282722},{"date":"2023-10-20","current":14.94053,"twenty":-35.232247,"median":-24.59436,"eighty":-14.914724,"marketCap":31749908394},{"date":"2023-10-27","current":16.35255,"twenty":-35.175876,"median":-24.58122,"eighty":-14.756101,"marketCap":34735661368},{"date":"2023-11-03","current":17.592659,"twenty":-35.129074,"median":-24.511377,"eighty":-14.616308,"marketCap":37469097190},{"date":"2023-11-10","current":18.939266,"twenty":-34.971061,"median":-24.417444,"eighty":-14.569406,"marketCap":40328691589},{"date":"2023-11-17","current":18.319814,"twenty":-34.968612,"median":-24.399566,"eighty":-14.535322,"marketCap":39361475836},{"date":"2023-11-24","current":18.189638,"twenty":-34.895357,"median":-24.342298,"eighty":-14.371526,"marketCap":39403528695},{"date":"2023-12-01","current":18.752497,"twenty":-34.737009,"median":-24.330293,"eighty":-14.199347,"marketCap":40791273036},{"date":"2023-12-08","current":16.771041,"twenty":-34.685609,"median":-24.255162,"eighty":-14.117346,"marketCap":36333670003},{"date":"2023-12-15","current":17.832719,"twenty":-34.615488,"median":-24.15298,"eighty":-14.060142,"marketCap":38856841531},{"date":"2023-12-22","current":16.203086,"twenty":-34.602221,"median":-24.100109,"eighty":-13.960331,"marketCap":35282348533},{"date":"2023-12-29","current":17.826838,"twenty":-34.566441,"median":-24.075355,"eighty":-13.84838,"marketCap":39025052966},{"date":"2024-01-05","current":16.831364,"twenty":-34.502078,"median":-24.025855,"eighty":-13.7643,"marketCap":36585987156},{"date":"2024-01-12","current":17.634525,"twenty":-34.43816,"median":-23.91516,"eighty":-13.515965,"marketCap":38352207225},{"date":"2024-01-19","current":16.051677,"twenty":-34.428025,"median":-23.817977,"eighty":-13.388012,"marketCap":34861819945},{"date":"2024-01-26","current":16.269899,"twenty":-34.417805,"median":-23.667454,"eighty":-13.261099,"marketCap":35198242815},{"date":"2024-02-02","current":15.531605,"twenty":-34.408725,"median":-23.587311,"eighty":-13.092715,"marketCap":33558181322},{"date":"2024-02-09","current":15.823479,"twenty":-34.287198,"median":-23.509747,"eighty":-12.88456,"marketCap":34357185639},{"date":"2024-02-16","current":17.001239,"twenty":-34.118192,"median":-23.29296,"eighty":-12.670051,"marketCap":36922410026},{"date":"2024-02-23","current":17.733723,"twenty":-34.052175,"median":-23.261464,"eighty":-12.429079,"marketCap":38310154366},{"date":"2024-03-01","current":18.170113,"twenty":-33.918444,"median":-23.222586,"eighty":-12.109337,"marketCap":39277370119},{"date":"2024-03-08","current":18.375936,"twenty":-33.875196,"median":-23.212231,"eighty":-11.784491,"marketCap":39739951566},{"date":"2024-03-15","current":20.221708,"twenty":-33.786096,"median":-23.186995,"eighty":-11.680404,"marketCap":43692920293},{"date":"2024-03-22","current":17.596046,"twenty":-33.777607,"median":-23.165857,"eighty":-11.598761,"marketCap":38772735813},{"date":"2024-03-28","current":17.863111,"twenty":-33.671621,"median":-23.133172,"eighty":-11.174522,"marketCap":39235317260},{"date":"2024-04-05","current":17.790526,"twenty":-33.631134,"median":-23.073507,"eighty":-10.781195,"marketCap":39050158637},{"date":"2024-04-12","current":19.515107,"twenty":-33.600204,"median":-23.002422,"eighty":-10.363031,"marketCap":42859930212},{"date":"2024-04-19","current":17.322126,"twenty":-33.582079,"median":-22.887987,"eighty":-9.922708,"marketCap":38011130026},{"date":"2024-04-26","current":19.239838,"twenty":-33.576561,"median":-22.815578,"eighty":-9.479287,"marketCap":42167244471},{"date":"2024-05-03","current":19.371749,"twenty":-33.573712,"median":-22.807081,"eighty":-9.18811,"marketCap":42427001624},{"date":"2024-05-10","current":19.700553,"twenty":-33.522448,"median":-22.755385,"eighty":-8.970402,"marketCap":43249565941},{"date":"2024-05-17","current":19.23578,"twenty":-33.345978,"median":-22.735553,"eighty":-8.780037,"marketCap":42167244471},{"date":"2024-05-24","current":14.667701,"twenty":-33.217784,"median":-22.607363,"eighty":-8.675073,"marketCap":32080008370},{"date":"2024-05-31","current":17.401421,"twenty":-33.106388,"median":-22.460124,"eighty":-8.554056,"marketCap":38097715744},{"date":"2024-06-07","current":16.096502,"twenty":-33.061925,"median":-22.417733,"eighty":-8.291628,"marketCap":35197094204},{"date":"2024-06-14","current":15.794192,"twenty":-33.047794,"median":-22.339227,"eighty":-8.117822,"marketCap":34504408463},{"date":"2024-06-21","current":14.159201,"twenty":-33.01008,"median":-22.315076,"eighty":-7.860137,"marketCap":30867808324},{"date":"2024-06-28","current":14.999486,"twenty":-32.90826,"median":-22.280642,"eighty":13.494356,"marketCap":32686108394},{"date":"2024-07-05","current":15.459781,"twenty":-32.881624,"median":-22.258985,"eighty":13.627238,"marketCap":33681844146},{"date":"2024-07-12","current":15.952998,"twenty":-32.86657,"median":-22.065202,"eighty":13.703744,"marketCap":34807458475},{"date":"2024-07-19","current":15.972541,"twenty":-32.832239,"median":-21.944137,"eighty":13.863497,"marketCap":34850751334},{"date":"2024-07-26","current":16.071567,"twenty":-32.814226,"median":-21.7966,"eighty":14.148348,"marketCap":35197094204},{"date":"2024-08-02","current":16.61499,"twenty":-32.811697,"median":-21.752014,"eighty":14.411832,"marketCap":36366001392},{"date":"2024-08-09","current":17.212345,"twenty":-32.808943,"median":-21.597174,"eighty":14.509977,"marketCap":37924544308},{"date":"2024-08-16","current":17.657405,"twenty":-32.804956,"median":-21.439655,"eighty":14.640353,"marketCap":38920280061},{"date":"2024-08-23","current":17.9547,"twenty":-32.79969,"median":-21.418042,"eighty":14.703604,"marketCap":39742844378},{"date":"2024-08-30","current":-52.624506,"twenty":-32.804956,"median":-21.417734,"eighty":14.818346,"marketCap":42513587341},{"date":"2024-09-06","current":-51.635037,"twenty":-32.832239,"median":-21.438942,"eighty":14.78042,"marketCap":41734315883},{"date":"2024-09-13","current":-66.216902,"twenty":-33.018625,"median":-21.520592,"eighty":14.703604,"marketCap":53380094900},{"date":"2024-09-20","current":-69.932725,"twenty":-33.173226,"median":-21.714319,"eighty":14.662246,"marketCap":56713645028},{"date":"2024-09-27","current":-71.531113,"twenty":-33.576561,"median":-21.771586,"eighty":14.652247,"marketCap":58358773662},{"date":"2024-10-04","current":-79.320454,"twenty":-33.638129,"median":-21.813706,"eighty":14.649255,"marketCap":64419773894},{"date":"2024-10-10","current":-69.213885,"twenty":-33.875196,"median":-21.986037,"eighty":14.648182,"marketCap":55847787852},{"date":"2024-10-18","current":-74.646599,"twenty":-34.399868,"median":-22.081407,"eighty":14.635134,"marketCap":59917316579},{"date":"2024-10-25","current":-77.719883,"twenty":-34.441314,"median":-22.265924,"eighty":14.560741,"marketCap":62380223732},{"date":"2024-11-01","current":-76.214752,"twenty":-34.685609,"median":-22.294,"eighty":14.556702,"marketCap":61213399403},{"date":"2024-11-08","current":-76.2814,"twenty":-34.971061,"median":-22.333531,"eighty":14.515997,"marketCap":60989010109},{"date":"2024-11-15","current":-78.00551,"twenty":-35.320815,"median":-22.40582,"eighty":14.505964,"marketCap":61707055850},{"date":"2024-11-22","current":-81.958791,"twenty":-35.480573,"median":-22.437728,"eighty":14.479729,"marketCap":64803628107},{"date":"2024-11-29","current":-83.036127,"twenty":-35.659842,"median":-22.470599,"eighty":14.463817,"marketCap":65611429565},{"date":"2024-12-06","current":-74.237179,"twenty":-35.878177,"median":-22.720101,"eighty":14.435399,"marketCap":58520727875},{"date":"2024-12-13","current":-72.615659,"twenty":-36.070462,"median":-22.745547,"eighty":14.396121,"marketCap":57129514252},{"date":"2024-12-20","current":-69.730236,"twenty":-36.160141,"median":-22.79318,"eighty":14.28027,"marketCap":54616354159},{"date":"2024-12-27","current":-68.121477,"twenty":-36.342788,"median":-22.81524,"eighty":14.230859,"marketCap":53314896254},{"date":"2025-01-03","current":-66.794572,"twenty":-36.589185,"median":-22.863096,"eighty":14.182431,"marketCap":52327583360},{"date":"2025-01-10","current":-64.575988,"twenty":-36.921451,"median":-22.916115,"eighty":14.151966,"marketCap":50397835432},{"date":"2025-01-17","current":-67.97132,"twenty":-37.388459,"median":-23.037405,"eighty":14.124517,"marketCap":53090506960},{"date":"2025-01-24","current":-71.487894,"twenty":-37.630978,"median":-23.112092,"eighty":14.06824,"marketCap":56187079217},{"date":"2025-01-28","current":-69.159217,"twenty":-37.749998,"median":-23.133265,"eighty":14.036856,"marketCap":54616354159},{"date":"2025-02-07","current":-74.204707,"twenty":-38.720974,"median":-23.179575,"eighty":13.91548,"marketCap":58296338581},{"date":"2025-02-14","current":-68.942526,"twenty":-39.742666,"median":-23.199597,"eighty":13.854976,"marketCap":54032941995},{"date":"2025-02-21","current":-78.532535,"twenty":-40.936164,"median":-23.213534,"eighty":13.833941,"marketCap":61886567285},{"date":"2025-02-28","current":-83.363188,"twenty":-41.78603,"median":-23.229233,"eighty":13.752998,"marketCap":65476795989},{"date":"2025-03-07","current":-82.972913,"twenty":-43.765472,"median":-23.273351,"eighty":13.720056,"marketCap":65431918130},{"date":"2025-03-14","current":-81.918752,"twenty":-44.36559,"median":-23.404228,"eighty":13.69943,"marketCap":64624116672},{"date":"2025-03-21","current":-77.113549,"twenty":-46.703645,"median":-23.571971,"eighty":13.681934,"marketCap":60809498674},{"date":"2025-03-28","current":-85.082441,"twenty":-50.561624,"median":-23.656456,"eighty":13.67268,"marketCap":66957765329},{"date":"2025-04-03","current":-139.968555,"twenty":-51.651807,"median":-23.75284,"eighty":13.662257,"marketCap":77100161418},{"date":"2025-04-11","current":-135.149196,"twenty":-52.531592,"median":-23.854164,"eighty":13.627238,"marketCap":73779199867},{"date":"2025-04-17","current":-136.201828,"twenty":-53.202931,"median":-23.974596,"eighty":13.597708,"marketCap":74452367749},{"date":"2025-04-25","current":-162.080631,"twenty":-54.264543,"median":-23.982021,"eighty":13.592632,"marketCap":88770184906},{"date":"2025-05-02","current":-143.58439,"twenty":-55.295104,"median":-23.989446,"eighty":13.587555,"marketCap":78807100452},{"date":"2025-05-09","current":-136.980788,"twenty":-56.345373,"median":-23.982021,"eighty":13.592632,"marketCap":75710466095},{"date":"2025-05-16","current":-134.501562,"twenty":-57.376977,"median":-23.982021,"eighty":13.592632,"marketCap":74947527196},{"date":"2025-05-23","current":-133.538341,"twenty":-57.747713,"median":-23.982021,"eighty":13.592632,"marketCap":74633375884},{"date":"2025-05-30","current":-133.993142,"twenty":-58.91872,"median":-23.982021,"eighty":13.592632,"marketCap":75216799748},{"date":"2025-06-06","current":-131.180073,"twenty":-59.359698,"median":-23.982021,"eighty":13.592632,"marketCap":73825558226},{"date":"2025-06-13","current":-152.810216,"twenty":-59.540166,"median":-23.982021,"eighty":13.592632,"marketCap":86032580619},{"date":"2025-06-20","current":-145.842175,"twenty":-59.540166,"median":-23.982021,"eighty":13.592632,"marketCap":81948613568},{"date":"2025-06-27","current":-147.346424,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":83025703780},{"date":"2025-07-04","current":-184.930979,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":104208477933},{"date":"2025-07-11","current":-180.493504,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":101605509923},{"date":"2025-07-18","current":-224.51725,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":126288827263},{"date":"2025-07-25","current":-237.059172,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":133828458741},{"date":"2025-08-01","current":-250.051759,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":140291000008},{"date":"2025-08-08","current":-255.97072,"twenty":-59.773257,"median":-23.989446,"eighty":13.587555,"marketCap":143971058230},{"date":"2025-08-15","current":-264.505775,"twenty":-59.98102,"median":-23.989446,"eighty":13.587555,"marketCap":148548691628},{"date":"2025-08-22","current":-283.614883,"twenty":-59.98102,"median":-23.989446,"eighty":13.587555,"marketCap":158781048634},{"date":"2025-08-29","current":-151.096607,"twenty":-60.061292,"median":-23.989446,"eighty":13.587555,"marketCap":139755257503},{"date":"2025-09-05","current":-154.217836,"twenty":-62.354796,"median":-23.989446,"eighty":13.587555,"marketCap":142500849327},{"date":"2025-09-12","current":-134.834957,"twenty":-64.590671,"median":-23.989446,"eighty":13.587555,"marketCap":124814900348},{"date":"2025-09-19","current":-129.155078,"twenty":-65.225568,"median":-24.062263,"eighty":13.587555,"marketCap":119472269927},{"date":"2025-09-26","current":-132.486221,"twenty":-66.989962,"median":-24.124656,"eighty":13.587555,"marketCap":122235699455},{"date":"2025-10-03","current":-139.242464,"twenty":-67.293654,"median":-24.261227,"eighty":13.582478,"marketCap":128775816004},{"date":"2025-10-10","current":-127.67557,"twenty":-67.910041,"median":-24.342298,"eighty":13.587555,"marketCap":117906326528},{"date":"2025-10-17","current":-122.384529,"twenty":-68.235995,"median":-24.417444,"eighty":13.587555,"marketCap":112932153377},{"date":"2025-10-24","current":-114.955731,"twenty":-68.842466,"median":-24.58122,"eighty":13.587555,"marketCap":106115693875},{"date":"2025-10-31","current":-112.991017,"twenty":-69.234459,"median":-24.630996,"eighty":13.587555,"marketCap":104457636158},{"date":"2025-11-07","current":-111.865223,"twenty":-69.783847,"median":-24.772153,"eighty":13.587555,"marketCap":103352264347},{"date":"2025-11-14","current":-118.110846,"twenty":-71.021734,"median":-24.903626,"eighty":13.587555,"marketCap":109431809308},{"date":"2025-11-21","current":-106.428879,"twenty":-71.496538,"median":-25.008455,"eighty":13.587555,"marketCap":98562319832},{"date":"2025-11-28","current":-121.801586,"twenty":-72.238759,"median":-25.173816,"eighty":13.587555,"marketCap":113208496330},{"date":"2025-12-05","current":-122.779771,"twenty":-72.794834,"median":-25.300444,"eighty":13.587555,"marketCap":114313868141},{"date":"2025-12-12","current":-122.948103,"twenty":-73.382927,"median":-25.403597,"eighty":13.587555,"marketCap":114682325412},{"date":"2025-12-19","current":-115.46697,"twenty":-74.211201,"median":-25.633881,"eighty":13.587555,"marketCap":107957980227},{"date":"2025-12-24","current":-110.590517,"twenty":-74.659967,"median":-25.640942,"eighty":13.587555,"marketCap":103720721617},{"date":"2026-01-02","current":-110.841788,"twenty":-75.482016,"median":-25.637411,"eighty":13.592632,"marketCap":104365521840},{"date":"2026-01-09","current":-124.521475,"twenty":-75.983701,"median":-25.679301,"eighty":13.547374,"marketCap":117537869257},{"date":"2026-01-16","current":-117.698232,"twenty":-76.738768,"median":-25.679301,"eighty":13.547374,"marketCap":111458324296},{"date":"2026-01-23","current":-113.429847,"twenty":-77.350039,"median":-25.679301,"eighty":13.547374,"marketCap":107313180004},{"date":"2026-01-30","current":-107.001444,"twenty":-78.004549,"median":-25.679301,"eighty":13.547374,"marketCap":101694206630},{"date":"2026-02-06","current":-97.546473,"twenty":-79.287468,"median":-25.773598,"eighty":13.494628,"marketCap":92943346458},{"date":"2026-02-13","current":-101.218847,"twenty":-80.266586,"median":-25.825195,"eighty":13.494537,"marketCap":96996376432},{"date":"2026-02-20","current":-105.022841,"twenty":-80.777808,"median":-25.722001,"eighty":13.494719,"marketCap":100496720501},{"date":"2026-02-27","current":-101.788736,"twenty":-81.405078,"median":-25.722001,"eighty":13.494719,"marketCap":98470205514},{"date":"2026-03-06","current":-102.999959,"twenty":-82.133452,"median":-25.722001,"eighty":13.494719,"marketCap":98838662784},{"date":"2026-03-13","current":-105.298763,"twenty":-83.363188,"median":-25.722001,"eighty":13.494719,"marketCap":101509977995},{"date":"2026-03-20","current":-110.878439,"twenty":-84.977693,"median":-25.773598,"eighty":13.494628,"marketCap":106484151145}],"updateTime":1774279959336},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09926\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1186315848","title":"Earning Preview: AKESO this quarter’s revenue is expected to increase by 0%, and institutional views are Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=1186315848","media":"Earnings Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1186315848?lang=en_us&edition=fundamental","pubTime":"2026-03-19 11:27","pubTimestamp":1773890855,"startTime":"0","endTime":"0","summary":"Abstract AKESO will report quarterly results on March 26, 2026 post-Market; this preview consolidates recent operating trends and available financial indicators to frame expectations for revenue,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: AKESO this quarter’s revenue is expected to increase by 0%, and institutional views are Neutral","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"1134869880","title":"Akeso (9926.HK) Schedules 26 Mar 2026 Board Meeting to Approve FY2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1134869880","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134869880?lang=en_us&edition=fundamental","pubTime":"2026-03-16 17:21","pubTimestamp":1773652898,"startTime":"0","endTime":"0","summary":"Akeso, Inc. (Stock Code: 9926) has announced that its board of directors will convene on Thursday, 26 March 2026. The meeting’s agenda is to consider and approve the consolidated annual results of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"2619453770","title":"Akeso board to review and approve full-year results","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453770","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619453770?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:46","pubTimestamp":1773650776,"startTime":"0","endTime":"0","summary":"A Board meeting at Akeso is scheduled for March 26, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL2WZbtm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU2778985437.USD","LU0348827113.USD","BK1161","LU1961090484.USD","LU0417516738.SGD","LU2476274308.USD","LU0348825331.USD","LU2399975544.HKD","IE00B543WZ88.USD","BK1574","09926","LU0561508036.HKD","LU0417516571.SGD","LU1720050803.USD","LU0348735423.USD","LU0348767384.USD","LU0634319403.HKD","LU0348766576.USD","LU2476274720.SGD","LU0348784397.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU1794554557.SGD","LU0348783233.USD","LU0417516902.SGD","LU2488822045.USD"],"gpt_icon":0},{"id":"1111812922","title":"AKESO Shares Climb Over 4% Again Following Clinical Trial Approval for First Trispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1111812922","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111812922?lang=en_us&edition=fundamental","pubTime":"2026-03-16 11:28","pubTimestamp":1773631697,"startTime":"0","endTime":"0","summary":"AKESO (09926) saw its share price rise more than 4% again. At the time of writing, the stock was up 4.26% to HK$114.9, with a turnover of HK$529 million. The increase follows recent news that the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348783233.USD","LU2476274308.USD","LU0348825331.USD","LU1720050803.USD","LU1794554557.SGD","LU2399975544.HKD","LU0540923850.HKD","BK4588","IE00BPRC5H50.USD","LU0348735423.USD","LU0417516902.SGD","BK1161","IE00B5MMRT66.SGD","BK4585","LU2476274720.SGD","LU0417516571.SGD","LU1961090484.USD","LU0348767384.USD","LU2488822045.USD","LU0348784397.USD","09926","VXUS","BK1574","LU0348827113.USD","LU2778985437.USD","LU0561508036.HKD","IE00B543WZ88.USD","LU0348766576.USD","LU0634319403.HKD","LU0417516738.SGD"],"gpt_icon":0},{"id":"2619870594","title":"Akeso wins NMPA IND clearance for AK150 solid tumor trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2619870594","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619870594?lang=en_us&edition=fundamental","pubTime":"2026-03-16 10:06","pubTimestamp":1773626766,"startTime":"0","endTime":"0","summary":"Akeso said China’s National Medical Products Administration cleared an investigational new drug application for its trispecific antibody candidate AK150. The clearance allows clinical trials in patients with advanced solid tumors.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL7CZVF6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU0417516571.SGD","LU0561508036.HKD","LU0348766576.USD","LU2476274308.USD","IE00B5MMRT66.SGD","09926","LU1720050803.USD","LU0348783233.USD","LU1961090484.USD","BK1574","LU0348825331.USD","LU2476274720.SGD","LU0348827113.USD","LU2399975544.HKD","LU0634319403.HKD","IE00B543WZ88.USD","LU1794554557.SGD","LU0417516738.SGD","LU2778985437.USD","LU0417516902.SGD","BK1161","LU0348784397.USD","LU0348767384.USD","LU0540923850.HKD","LU0348735423.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"1142485530","title":"AKESO Shares Surge Nearly 8% in Morning Session as First-in-Class Trispecific Antibody AK150 Enters Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1142485530","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142485530?lang=en_us&edition=fundamental","pubTime":"2026-03-10 09:46","pubTimestamp":1773107201,"startTime":"0","endTime":"0","summary":"AKESO (09926) saw its stock rise nearly 8% during the morning trading session. As of the time of writing, the share price had increased by 7.33% to HK$111.3, with a trading volume of HK$276 million....","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a3f44e86c3bddb2de2b4a93e8a962fb5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348783233.USD","LU2476274308.USD","LU0348825331.USD","LU1720050803.USD","LU1794554557.SGD","LU2399975544.HKD","LU0540923850.HKD","BK4588","IE00BPRC5H50.USD","LU0348735423.USD","LU0417516902.SGD","BK1161","IE00B5MMRT66.SGD","BK4585","LU2476274720.SGD","LU0417516571.SGD","LU1961090484.USD","LU0348767384.USD","LU2488822045.USD","LU0348784397.USD","09926","VXUS","BK1574","LU0348827113.USD","LU2778985437.USD","LU0561508036.HKD","IE00B543WZ88.USD","LU0348766576.USD","LU0634319403.HKD","LU0417516738.SGD"],"gpt_icon":0},{"id":"2618642416","title":"Assessing Akeso (SEHK:9926) Valuation After Cervical Cancer Data And New INOVIO Trial Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2618642416","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618642416?lang=en_us&edition=fundamental","pubTime":"2026-03-08 22:15","pubTimestamp":1772979314,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) is back in focus after presenting long term survival data for its bispecific antibody cadonilimab in advanced cervical cancer and announcing a new glioblastoma combo trial collaboration with INOVIO.\nSee our latest analysis for Akeso.\nAkeso shares closed at HK$107.3 after a 5.2% 1 day share price return. While the 30 day share price return of 6.34% contrasts with a 13.75% decline over 90 days, the 47.19% 1 year total shareholder return and 173.03% 3 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-valuation-after-cervical-cancer-dat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-valuation-after-cervical-cancer-dat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0634319403.HKD","LU1961090484.USD","IE00B543WZ88.USD","LU2399975544.HKD","LU2778985437.USD","LU2476274308.USD","LU2476274720.SGD","LU2488822045.USD","LU0348767384.USD","IE00B5MMRT66.SGD","LU0540923850.HKD","LU1720050803.USD","LU0348784397.USD","09926","LU0348766576.USD","IE00BPRC5H50.USD","LU0348825331.USD","BK1574","LU0561508036.HKD","LU0348783233.USD","BK1161","LU0348735423.USD","LU0348827113.USD","LU0417516571.SGD","LU0417516902.SGD","LU0417516738.SGD","LU1794554557.SGD"],"gpt_icon":0},{"id":"1131078244","title":"AKESO Shares Surge Over 6% in Morning Session on Novel Brain Cancer Treatment Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=1131078244","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131078244?lang=en_us&edition=fundamental","pubTime":"2026-03-05 10:38","pubTimestamp":1772678314,"startTime":"0","endTime":"0","summary":"AKESO (09926) saw its shares rise more than 6% during the morning trading session. At the time of writing, the stock was up 6.3%, trading at HK$101.3, with a turnover of HK$343 million. The increase...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU0348767384.USD","IE00B543WZ88.USD","LU2778985437.USD","LU0417516902.SGD","LU0561508036.HKD","LU0634319403.HKD","LU2476274720.SGD","LU2476274308.USD","BK4585","LU0417516571.SGD","BK4588","LU0348766576.USD","09926","LU0348784397.USD","DNA","LU2399975544.HKD","LU0348735423.USD","LU0348825331.USD","BK4139","BK1574","LU0348783233.USD","VXUS","LU1720050803.USD","BK1161","BK4109","LU1794554557.SGD","LU0540923850.HKD","LU1961090484.USD","IE00B5MMRT66.SGD","VT","IE00BPRC5H50.USD","LU0417516738.SGD","BK4121","LU0348827113.USD"],"gpt_icon":0},{"id":"2617993975","title":"Akeso Reports 100% 24-Month Overall Survival in Complete Responders With Cadonilimab in Phase II Cervical Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2617993975","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617993975?lang=en_us&edition=fundamental","pubTime":"2026-03-05 10:26","pubTimestamp":1772677611,"startTime":"0","endTime":"0","summary":"Akeso Inc. reported updated long-term survival results from the China registrational Phase II COMPASSION-03  study evaluating cadonilimab monotherapy in patients with recurrent or metastatic cervical cancer who had failed prior platinum-containing chemotherapy. The company said the data were presented as a late-breaking oral presentation at ESGO 2026, based on a median follow-up of 26.5 months in 99 efficacy-evaluable patients. In a best overall response-stratified analysis, complete responders had a 24-month overall survival rate of 100% with median overall survival not reached, while partial responders had a 24-month overall survival rate of 63% with median overall survival not reached. Across the overall population, Akeso reported a median overall survival of 17.5 months and 18- and 24-month overall survival rates of 47.8% and 40.9%, respectively.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL1f0Gzd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU2778985437.USD","BK1574","LU0348767384.USD","BK1161","LU0417516902.SGD","LU0348735423.USD","LU0634319403.HKD","LU0348784397.USD","LU2476274308.USD","LU1720050803.USD","LU0417516738.SGD","LU0540923850.HKD","LU1794554557.SGD","IE00BPRC5H50.USD","LU2488822045.USD","LU2399975544.HKD","LU0348783233.USD","IE00B543WZ88.USD","LU1961090484.USD","LU0417516571.SGD","LU0348827113.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","09926","LU0348766576.USD","LU0561508036.HKD"],"gpt_icon":0},{"id":"2617459607","title":"Cadonilimab Achieves 100% 24-Month Os in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase Ii Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2617459607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617459607?lang=en_us&edition=fundamental","pubTime":"2026-03-05 10:26","pubTimestamp":1772677595,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nTUA3ZZRZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BPRC5H50.USD","LU0561508036.HKD","LU0417516902.SGD","LU0417516571.SGD","LU0348784397.USD","LU0348767384.USD","LU2778985437.USD","LU2476274720.SGD","LU2399975544.HKD","BK1161","IE00B543WZ88.USD","LU0348825331.USD","LU0417516738.SGD","LU0348827113.USD","LU1794554557.SGD","LU0348766576.USD","LU2476274308.USD","LU0348735423.USD","BK1574","LU0540923850.HKD","09926","IE00B5MMRT66.SGD","LU0348783233.USD","LU0634319403.HKD","LU2488822045.USD","LU1961090484.USD","LU1720050803.USD"],"gpt_icon":0},{"id":"2616355590","title":"Akeso, INOVIO team up to test cadonilimab plus INO-5412 in GBM trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2616355590","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616355590?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:53","pubTimestamp":1772632390,"startTime":"0","endTime":"0","summary":"Akeso Inc. and INOVIO have entered into a clinical trial collaboration and supply agreement to evaluate Akeso’s cadonilimab, a PD-1/CTLA-4 bispecific antibody, in combination with INOVIO’s DNA immunotherapy candidate INO-5412 for the treatment of glioblastoma. The regimen will be studied in the Phase II INSIGhT adaptive platform trial sponsored by Dana-Farber Cancer Institute, with dosing expected to begin in the second half of 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL8Jjn2K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INO","BK4568","LU0348767384.USD","09926","BK4139","LU2488822045.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","BK4583","LU1794554557.SGD","LU2476274308.USD","BK1574","LU0348783233.USD","LU2778985437.USD","LU0634319403.HKD","LU0417516738.SGD","LU0417516571.SGD","LU0348784397.USD","LU2476274720.SGD","LU1720050803.USD","LU0561508036.HKD","LU1961090484.USD","LU0348766576.USD","BK1161","LU0348825331.USD","LU0348735423.USD","LU0540923850.HKD","LU0348827113.USD","IE00B543WZ88.USD","LU2399975544.HKD"],"gpt_icon":0},{"id":"2616558296","title":"BRIEF-Inovio And Akeso Announce Clinical Collaboration To Advance Novel Combination Therapy For Glioblastoma (Gbm)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616558296","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616558296?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:06","pubTimestamp":1772629573,"startTime":"0","endTime":"0","summary":"BRIEF-Inovio And Akeso Announce Clinical Collaboration To Advance Novel Combination Therapy For Glioblastoma (Gbm)March 4 (Reuters) - Akeso Inc 9926.HK:INOVIO AND AKESO ANNOUNCE CLINICAL COLLABORATION","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA4TKXJZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU2399975544.HKD","LU2476274720.SGD","BK4583","LU0348766576.USD","INO","BK4568","LU1961090484.USD","BK1574","LU0348783233.USD","LU2778985437.USD","LU0561508036.HKD","LU1720050803.USD","LU0417516902.SGD","LU2488822045.USD","IE00BPRC5H50.USD","LU0348827113.USD","LU0634319403.HKD","09926","LU1794554557.SGD","LU0417516738.SGD","IE00B543WZ88.USD","LU0348767384.USD","IE00B5MMRT66.SGD","LU2476274308.USD","LU0417516571.SGD","LU0348784397.USD","LU0348735423.USD","LU0540923850.HKD","BK1161","BK4139"],"gpt_icon":0},{"id":"2616581105","title":"Inovio and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616581105","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616581105?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:05","pubTimestamp":1772629500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA4TKXJZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BPRC5H50.USD","LU2476274720.SGD","LU1961090484.USD","LU0634319403.HKD","LU0417516738.SGD","BK4568","LU2488822045.USD","LU0348767384.USD","BK4139","LU2399975544.HKD","INO","LU0417516571.SGD","LU2476274308.USD","BK1574","BK1161","LU1720050803.USD","LU0561508036.HKD","BK4583","LU2778985437.USD","LU0348766576.USD","LU0348825331.USD","09926","LU1794554557.SGD","LU0348784397.USD","LU0348783233.USD","LU0348827113.USD","LU0348735423.USD","LU0540923850.HKD","LU0417516902.SGD","IE00B543WZ88.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2616558476","title":"Inovio - Dosing in Combination Therapy Trial Expected to Begin in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616558476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616558476?lang=en_us&edition=fundamental","pubTime":"2026-03-04 21:05","pubTimestamp":1772629500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nTUA4TKXJZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0417516902.SGD","LU0348766576.USD","LU2778985437.USD","LU2488822045.USD","LU0634319403.HKD","BK4568","BK4583","BK1574","LU2476274308.USD","LU0348825331.USD","LU2399975544.HKD","LU0348827113.USD","LU0348784397.USD","LU2476274720.SGD","LU0348783233.USD","LU0417516738.SGD","LU0561508036.HKD","INO","LU0348767384.USD","LU1720050803.USD","LU0417516571.SGD","LU0348735423.USD","BK4139","IE00BPRC5H50.USD","BK1161","LU0540923850.HKD","IE00B543WZ88.USD","LU1794554557.SGD","LU1961090484.USD","09926","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"1192298705","title":"AKESO (09926) Announces Monthly Return with No Changes to Share Capital or Issued Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1192298705","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192298705?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:46","pubTimestamp":1772617583,"startTime":"0","endTime":"0","summary":"AKESO (09926) released its Monthly Return for the month ended 28 February 2026. The authorized share capital remained at 5.00 billion ordinary shares, each with a par value of USD 0.00001, totaling...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"1159547038","title":"AKESO Shares Climb Nearly 5% in Morning Session Following NDA Acceptance for Mandoqi Monoclonal Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1159547038","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159547038?lang=en_us&edition=fundamental","pubTime":"2026-02-27 13:51","pubTimestamp":1772171489,"startTime":"0","endTime":"0","summary":"AKESO (09926) saw its shares rise nearly 5% during morning trading. At the time of writing, the stock was up 4.22%, trading at HK$106.2, with a turnover of HK$456 million. The increase follows news...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU0417516571.SGD","LU0348827113.USD","LU1794554557.SGD","BK1574","VXUS","LU2476274720.SGD","LU0348783233.USD","LU0348766576.USD","LU0634319403.HKD","LU0540923850.HKD","LU0348784397.USD","LU0417516902.SGD","IE00BPRC5H50.USD","LU2399975544.HKD","LU1961090484.USD","LU0348767384.USD","09926","LU1720050803.USD","LU0561508036.HKD","LU2476274308.USD","LU0348735423.USD","LU2488822045.USD","LU2778985437.USD","BK4585","BK4588","LU0348825331.USD","IE00B543WZ88.USD","LU0417516738.SGD","VT","BK1161"],"gpt_icon":0},{"id":"2611120049","title":"Assessing Akeso (SEHK:9926) Valuation After AK139 Trial Approval And Ivonescimab Breakthrough Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2611120049","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611120049?lang=en_us&edition=fundamental","pubTime":"2026-02-15 23:23","pubTimestamp":1771168997,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) has just received approval in China to start Phase II trials for AK139, a first in class IL-4Ra/ST2 bispecific antibody, targeting seven respiratory and autoimmune conditions.\nSee our latest analysis for Akeso.\nInvestors seem to be weighing Akeso's busy clinical calendar against recent volatility, with a 1 day share price return of 1.54% and 7 day return of 4.36% following the AK139 and ivonescimab updates. The 1 year total shareholder return of 74.92% points to strong...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-valuation-after-ak139-trial-approva","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-valuation-after-ak139-trial-approva","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2399975544.HKD","BK1574","LU1961090484.USD","LU1720050803.USD","LU0348784397.USD","LU0417516902.SGD","LU0348735423.USD","LU0348767384.USD","LU0348783233.USD","LU2778985437.USD","LU1794554557.SGD","LU0417516738.SGD","LU0348827113.USD","LU0348825331.USD","LU2488822045.USD","BK1161","LU0417516571.SGD","LU0634319403.HKD","LU2476274308.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","09926","LU0540923850.HKD","LU2476274720.SGD","LU0348766576.USD","IE00B5MMRT66.SGD","LU0561508036.HKD"],"gpt_icon":0},{"id":"2610598760","title":"Akeso Receives Chinese Approval to Begin Phase II Trials of IL-4Rα/ST2 Bispecific Antibody Across Seven Indications","url":"https://stock-news.laohu8.com/highlight/detail?id=2610598760","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610598760?lang=en_us&edition=fundamental","pubTime":"2026-02-11 17:02","pubTimestamp":1770800555,"startTime":"0","endTime":"0","summary":"Akeso Inc. has received approval from the National Medical Products Administration to initiate Phase II clinical trials for its bispecific antibody AK139 in China. The trials will cover seven indications, including chronic obstructive pulmonary disease , severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, chronic rhinosinusitis with nasal polyps, moderate-to-severe atopic dermatitis, and prurigo nodularis. AK139 is the first clinical-stage antibody to target both IL-4Rα and ST2 pathways, and the Phase II studies aim to evaluate its therapeutic potential in respiratory and autoimmune diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL8jL4rt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","LU0348783233.USD","LU0348735423.USD","LU0561508036.HKD","LU2476274720.SGD","LU0417516571.SGD","LU2488822045.USD","IE00B543WZ88.USD","LU0348825331.USD","LU0348827113.USD","LU0540923850.HKD","09926","LU1720050803.USD","LU0417516738.SGD","LU0634319403.HKD","LU0348784397.USD","LU0348767384.USD","LU2778985437.USD","BK1574","IE00B5MMRT66.SGD","BK1161","IE00BPRC5H50.USD","LU0417516902.SGD","LU2399975544.HKD","LU2476274308.USD","LU0348766576.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2609653238","title":"Akeso Reports Promising Phase III Results for Ivonescimab in Advanced Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2609653238","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609653238?lang=en_us&edition=fundamental","pubTime":"2026-02-06 10:27","pubTimestamp":1770344844,"startTime":"0","endTime":"0","summary":"Akeso Inc. has announced that its bispecific antibody ivonescimab has received its fifth Breakthrough Therapy Designation from the National Medical Products Administration  of China for use in combination with chemotherapy as a first-line treatment for advanced biliary tract cancer . This designation follows previous recognitions for indications in lung cancer and triple-negative breast cancer. A randomized, controlled, multicenter Phase III clinical study  is currently underway, comparing ivonescimab plus chemotherapy to durvalumab plus chemotherapy for first-line treatment of advanced BTC. Patient enrollment for this trial has been completed. Results from a Phase 1b/II study were presented at the 2024 American Society of Clinical Oncology  Annual Meeting, showing an objective response rate of 63.6% and a disease control rate of 100% for ivonescimab plus chemotherapy. The regimen also demonstrated a median progression-free survival of 8.5 months and a median overall survival of 16.8 m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL3MwHJr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0540923850.HKD","IE00B543WZ88.USD","LU0348783233.USD","09926","LU0348767384.USD","LU2399975544.HKD","LU2476274308.USD","LU0417516902.SGD","LU0634319403.HKD","LU0348784397.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU0348766576.USD","IE00B5MMRT66.SGD","LU1961090484.USD","LU0561508036.HKD","LU1720050803.USD","LU0348735423.USD","LU2778985437.USD","LU0348827113.USD","LU2488822045.USD","LU1794554557.SGD","LU0417516738.SGD","LU0348825331.USD","BK1574","LU2476274720.SGD"],"gpt_icon":0},{"id":"2609323885","title":"Akeso startet Phase-III-Studie mit Ivonescimab zur Erstlinienbehandlung von fortgeschrittenem Gallengangskrebs","url":"https://stock-news.laohu8.com/highlight/detail?id=2609323885","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609323885?lang=en_us&edition=fundamental","pubTime":"2026-02-06 10:27","pubTimestamp":1770344844,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire  on February 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL5KgrXt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","BK1161","LU0348783233.USD","LU0540923850.HKD","LU2488822045.USD","LU0348825331.USD","LU0348827113.USD","LU0417516738.SGD","IE00BPRC5H50.USD","09926","LU0348766576.USD","LU1794554557.SGD","LU1720050803.USD","LU2476274308.USD","LU0348735423.USD","BK1574","IE00B5MMRT66.SGD","LU2399975544.HKD","LU2778985437.USD","LU2476274720.SGD","LU0634319403.HKD","LU0417516571.SGD","LU0561508036.HKD","LU0417516902.SGD","IE00B543WZ88.USD","LU0348767384.USD","LU0348784397.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":101,"code":"91000000","status":"200"}]}}